drugset / Trial / NCT03212170
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
Phase 2
Completed
21 enrolled
University of Wisconsin, Madison
National Center for Advancing Translational Sciences (NCATS) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The goal of this research is to test the accuracy of PET/MRI imaging with 18F-fluorofuranylnorprogesterone (FFNP) for measuring progesterone receptor (PR) expression in patients with invasive breast cancer. The hypothesis is that FFNP SUVmax from PET/MRI will correlate well against the semi-quantitative PR immunohistochemistry score.
Timeline
- Start
- 2017-12-13
- Primary completion
- 2024-11-14
- Completion
- 2024-11-14
Outcome
Missed primary endpoint
registry NUMBER FFNP PET/MRI: 0.3215 correlation coefficient (rho) NCT03212170 ↗
registry analysis (other test); FFNP PET/MRI; p = 0.1347; two-sided hypothesis test NCT03212170 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-fluorofuranylnorprogesterone | Diagnostic / imaging agent | — | — |